Feed ONCO
ON

Onconetix, Inc.

ONCO · NASDAQ

$0.68 +6.07% (+$0.04)
1M +4.13%
Market Cap $2.35M
P/E Ratio -
Div. Yield -
ROE 91.95%

Bulios Fair Price

$0.85

24.4% upside

Current Price

$0.68

Undervalued Fair Value Overvalued

According to Bulios Fair Price, ONCO is currently undervalued relative to its market price. How does it work?

Unlock fair price

Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?

Piotroski F-Score Weak
1/9
Valuation
75 /100
Cheap
P/S 3.63x
P/B 0.17x
P/E N/A
Growth
0 /100
Declining
Book val. growth 11.03%
EPS growth N/A
Rev. growth N/A
Profitability
20 /100
Weak
Gross margin 80.40%
Net margin 1,578.79%
Op. margin 1,265.55%
Quality
0 /100
Poor
ROIC 59.86%
ROE 91.95%
ROA 62.07%
Debt
69 /100
Low
Debt/Equity 0.01x
Current ratio 2.21x
Int. coverage -31.79x
Stability
1 /100
Unstable
Beta 2.68x
EPS volatility 4,170.70%
Profitable years 0

Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more

Ask StockBot about ONCO
Online

About the company

Onconetix, Inc. is a commercial stage biotechnology company, which engages in the research, development and commercialization of proprietary therapeutics, diagnostics and services for clinicians and patients for oncology. The company was founded in October 2018 and is headquartered in Cincinnati, OH.

Sector

Healthcare

Industry

Biotechnology

CEO

David Allan White

Employees

2

Headquarters

Cincinnati

Upcoming events

12 NOV

Earnings

Upcoming earnings report

50d

We use essential cookies to run the website and optional analytics cookies to measure usage. See our Privacy Policy.